Lifevantage (LFVN) Competitors

Niagen Bioscience presently has a consensus target price of $10.33, indicating a potential upside of 214.08%. Lifevantage has a consensus target price of $5.50, indicating a potential downside of 13.52%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Niagen Bioscience is more favorable than Lifevantage.

Niagen Bioscience has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Niagen Bioscience has a net margin of 12.39% compared to Lifevantage's net margin of 2.78%. Lifevantage's return on equity of 21.63% beat Niagen Bioscience's return on equity.

Niagen Bioscience has higher earnings, but lower revenue than Lifevantage. Lifevantage is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Lifevantage had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 9 mentions for Lifevantage and 5 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.62 beat Lifevantage's score of -0.15 indicating that Niagen Bioscience is being referred to more favorably in the media.

Lifevantage has a net margin of 2.78% compared to USANA Health Sciences' net margin of -2.43%. Lifevantage's return on equity of 21.63% beat USANA Health Sciences' return on equity.

USANA Health Sciences has higher revenue and earnings than Lifevantage. USANA Health Sciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Lifevantage has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, USANA Health Sciences has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

In the previous week, Lifevantage had 7 more articles in the media than USANA Health Sciences. MarketBeat recorded 9 mentions for Lifevantage and 2 mentions for USANA Health Sciences. USANA Health Sciences' average media sentiment score of 0.77 beat Lifevantage's score of -0.15 indicating that USANA Health Sciences is being referred to more favorably in the news media.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 0.8% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lifevantage currently has a consensus target price of $5.50, indicating a potential downside of 13.52%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts plainly believe Lifevantage is more favorable than USANA Health Sciences.

Nature's Sunshine Products has higher revenue and earnings than Lifevantage. Nature's Sunshine Products is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Nature's Sunshine Products has a net margin of 3.68% compared to Lifevantage's net margin of 2.78%. Lifevantage's return on equity of 21.63% beat Nature's Sunshine Products' return on equity.

79.4% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 3.1% of Nature's Sunshine Products shares are held by company insiders. Comparatively, 22.0% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Lifevantage had 6 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 9 mentions for Lifevantage and 3 mentions for Nature's Sunshine Products. Nature's Sunshine Products' average media sentiment score of 1.86 beat Lifevantage's score of -0.15 indicating that Nature's Sunshine Products is being referred to more favorably in the media.

Nature's Sunshine Products has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Nature's Sunshine Products currently has a consensus price target of $30.50, indicating a potential upside of 114.64%. Lifevantage has a consensus price target of $5.50, indicating a potential downside of 13.52%. Given Nature's Sunshine Products' stronger consensus rating and higher possible upside, research analysts plainly believe Nature's Sunshine Products is more favorable than Lifevantage.

Lifevantage has a net margin of 2.78% compared to Nu Skin Enterprises' net margin of -15.73%. Lifevantage's return on equity of 21.63% beat Nu Skin Enterprises' return on equity.

In the previous week, Lifevantage had 9 more articles in the media than Nu Skin Enterprises. MarketBeat recorded 9 mentions for Lifevantage and 0 mentions for Nu Skin Enterprises. Nu Skin Enterprises' average media sentiment score of 0.00 beat Lifevantage's score of -0.15 indicating that Nu Skin Enterprises is being referred to more favorably in the media.

Nu Skin Enterprises has higher revenue and earnings than Lifevantage. Nu Skin Enterprises is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Nu Skin Enterprises has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

82.8% of Nu Skin Enterprises shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 2.8% of Nu Skin Enterprises shares are held by insiders. Comparatively, 22.0% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nu Skin Enterprises pays an annual dividend of $0.24 per share and has a dividend yield of 4.9%. Lifevantage pays an annual dividend of $0.20 per share and has a dividend yield of 3.1%. Nu Skin Enterprises pays out -5.4% of its earnings in the form of a dividend. Lifevantage pays out 50.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Lifevantage has raised its dividend for 3 consecutive years. Nu Skin Enterprises is clearly the better dividend stock, given its higher yield and lower payout ratio.

Lifevantage has a consensus target price of $5.50, indicating a potential downside of 13.52%. Given Lifevantage's stronger consensus rating and higher probable upside, analysts plainly believe Lifevantage is more favorable than Nu Skin Enterprises.